Explore

Trendline Trendline
Curis Reports Promising Results from AML Triplet Study with Emavusertib

Curis Reports Promising Results from AML Triplet Study with Emavusertib

Curis Reports Promising Results from AML Triplet Study with Emavusertib
Rapid Read Rapid Read
Genentech's Giredestrant Shows Promise in Reducing Breast Cancer Recurrence Risk

Genentech's Giredestrant Shows Promise in Reducing Breast Cancer Recurrence Risk

Genentech, a member of the Roche Group, has announced promising results from its Phase III lidERA Breast Cancer study. The study evaluated the efficacy of giredestrant, an investigational oral selective estrogen receptor degrader (SERD), as an adjuvant endocrine treatment for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, early-stage breast cancer. The interim analysis revealed that giredestrant significantly reduced the risk of invasive disease recurrence or death by 30% compared to standard-of-care endocrine therapy. This marks a significant advancement in endocrine therapy, the first in over 20 years, for early-stage ER-positive breast cancer, which accounts for approximately 70% of breast cancer cases. The results were presented at the 2025 San Antonio Breast Cancer Symposium.
Trendline Trendline
Eli Lilly's Experimental Obesity Drug Shows Promising Weight Loss Results

Eli Lilly's Experimental Obesity Drug Shows Promising Weight Loss Results

Eli Lilly's Experimental Obesity Drug Shows Promising Weight Loss Results
Rapid Read Rapid Read
Galderma Initiates Phase II Study on Nemolizumab for Chronic Pruritus of Unknown Origin in the U.S.

Galderma Initiates Phase II Study on Nemolizumab for Chronic Pruritus of Unknown Origin in the U.S.

Galderma has announced the enrollment of the first patient in a Phase II study to evaluate the efficacy and safety of nemolizumab for treating Chronic Pruritus of Unknown Origin (CPUO). This condition is characterized by a persistent itch lasting more than six weeks without a known cause, significantly affecting patients' quality of life due to severe itch, sleep deprivation, and mental distress. The study, taking place in the United States, aims to explore nemolizumab's potential in addressing this underdiagnosed condition, which currently lacks approved treatments. Nemolizumab, a monoclonal antibody, targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a cytokine involved in driving itch. The study is a randomized, double-blind, placebo-controlled trial designed to support the progression of nemolizumab to late-stage development.
Rapid Read Rapid Read
Privo Technologies Initiates Dosing in Clinical Trial for Oral Cavity Cancer Treatment

Privo Technologies Initiates Dosing in Clinical Trial for Oral Cavity Cancer Treatment

Privo Technologies, Inc. has commenced dosing the first patient in its clinical trial for PRV131, a nanoengineered intratumoral cisplatin injectable aimed at treating T1–T3 oral squamous cell carcinoma (OSCC). This trial, part of the Phase 1/2 Dose Escalation and Dose Optimization Run-In Study (Arm 3 of CLN-004), seeks to evaluate the safety, preliminary efficacy, tolerability, and pharmacokinetics of PRV131. The treatment is designed to shrink tumors before surgery, potentially improving surgical outcomes and preserving oral tissue. PRV131 delivers high concentrations of cisplatin directly to tumors, minimizing systemic exposure and aiming to reduce the morbidity associated with traditional surgical approaches.
Trendline Trendline
Bantam Pharmaceutical Begins Phase 1 Trial for Cancer Drug BTM-3566 in Toronto

Bantam Pharmaceutical Begins Phase 1 Trial for Cancer Drug BTM-3566 in Toronto

Bantam Pharmaceutical Begins Phase 1 Trial for Cancer Drug BTM-3566 in Toronto
Rapid Read Rapid Read
Fasting Enhances Breast Cancer Therapy Efficacy Through Glucocorticoid Activation

Fasting Enhances Breast Cancer Therapy Efficacy Through Glucocorticoid Activation

Recent research has shown that fasting can enhance the efficacy of breast cancer therapies by activating glucocorticoids. The study, conducted on mice, found that fasting reduced levels of insulin, IGF1, and leptin, which are factors that can promote tumor growth. By lowering these factors, fasting improved the effectiveness of breast cancer treatments, leading to reduced tumor size. The research highlights the potential of dietary interventions as a complementary approach to traditional cancer therapies. The study was conducted in accordance with ethical guidelines and involved various experimental models to assess the impact of fasting on tumor growth and treatment efficacy.
Trendline Trendline
Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Phase 3 Trial

Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Phase 3 Trial

Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Phase 3 Trial
Rapid Read Rapid Read
Study Highlights Prognostic Impact of ERBB2 Amplification in Metastatic Colorectal Cancer

Study Highlights Prognostic Impact of ERBB2 Amplification in Metastatic Colorectal Cancer

A recent study has evaluated the frequency and impact of ERBB2 amplification in metastatic colorectal cancer (mCRC) using a real-world dataset. The findings indicate that patients with ERBB2 amplification, particularly those with left-sided RAS/BRAF wild-type and non-MSI-H mCRC, experience worse real-world progression-free survival (rwPFS) following first-line treatment. This study is the first to assess the prognostic impact of ERBB2 amplification in first-line treatment of mCRC using a clinico-genomic database. The study confirms that HER2-positive mCRC is a rare molecular subset, with ERBB2 amplification observed in 3.1% of cases. Despite the poor prognosis associated with ERBB2 amplification, no significant difference in overall survival (rwOS) was observed between ERBB2 amp+ and amp- groups. The study suggests that current treatment options may be insufficient for HER2-positive mCRC, highlighting the need for HER2-targeted therapies.
Trendline Trendline
Regeneron Advances Lynozyfic for Untreated Multiple Myeloma with Promising Study Results

Regeneron Advances Lynozyfic for Untreated Multiple Myeloma with Promising Study Results

Regeneron Advances Lynozyfic for Untreated Multiple Myeloma with Promising Study Results
Rapid Read Rapid Read
Aleta Biotherapeutics and Cancer Research UK Report Promising Results in B-Cell Malignancy Trial

Aleta Biotherapeutics and Cancer Research UK Report Promising Results in B-Cell Malignancy Trial

Aleta Biotherapeutics, in collaboration with Cancer Research UK's Centre for Drug Development, has announced promising results from a phase I/II clinical trial of their CAR T-cell engager biologic, ALETA-001. The trial targets patients with B-cell malignancies who have previously undergone anti-CD19 CAR T-cell therapy. The study, conducted across multiple sites in the UK, aims to evaluate the safety and efficacy of ALETA-001. Preliminary findings indicate a highly tolerable safety profile and encouraging efficacy responses in patients with refractory or relapsed disease. The trial involves dose escalation to determine the optimal dose for further study. The results suggest that ALETA-001 can enhance the effectiveness of existing CAR T-cell therapies by increasing CD19 antigen density, potentially offering a new therapeutic option for patients who relapse after initial CAR T-cell treatment.
Rapid Read Rapid Read
Gallop Oncology Reports Promising Phase 1b Trial Results for LYT-200 in AML and MDS Patients

Gallop Oncology Reports Promising Phase 1b Trial Results for LYT-200 in AML and MDS Patients

Gallop Oncology, a company founded by PureTech Health, has announced positive initial results from a Phase 1b clinical trial of LYT-200, a monoclonal antibody, in patients with relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The trial demonstrated favorable tolerability and strong efficacy, with an initial median overall survival of 13.2 months in the combination cohort, significantly exceeding the expected survival of less than 2.5 months in similar settings. The trial included patients with high-risk mutations, indicating potential broad applicability of LYT-200. The findings support the advancement of LYT-200 into a potentially registrational Phase 2 trial, with further details to be shared at the upcoming American Society of Hematology Annual Meeting.